Explore the Australian Prescriber issue: Volume 49 Issue 1.

This February issue features an editorial and an article about psychotropic medicines in people with cognitive disability or impairment. Other articles address pharmacological management of ADHD in adults; a critical appraisal of intra-articular hyaluronic acid injections for symptomatic osteoarthritis; managing infection risk associated with immunosuppressive therapies; and secondary prevention of acute coronary syndromes. The new drugs discuss Ivosidenib for cholangiocarcinoma and acute myeloid leukaemia and Vutrisiran for hereditary transthyretin-mediated amyloidosis.

The February issue features:

• Defining psychotropic medicines in aged and disability care
• Appropriate use of psychotropic medicines in aged and disability care
• Pharmacological management of attention deficit hyperactivity disorder in adults
• Intra-articular hyaluronic acid for osteoarthritis – is it effective?
• Preventing infections in immunosuppressed patients
• Secondary prevention of acute coronary syndromes: summary of a new Australian guideline

New drugs:

• Ivosidenib for cholangiocarcinoma and acute myeloid leukaemia
• Vutrisiran for hereditary transthyretin-mediated amyloidosis

The Australian Prescriber Podcast is an easy way to stay in the know, as it dives into some of the many great articles that Australian Prescriber features every two months. Listen to recent episodes on Testing for human immunodeficiency virus and Top 10 drugs 2024-25.

RACGP members can now claim CPD hours for all Australian Prescriber articles and podcast episodes published in 2025-26. Whether you’re catching up on clinical insights or listening on the go, your learning counts. Log your CPD hours by reading the February issue of Australian Prescriber.

Join the 100,000 + healthcare professionals who trust and rely on Australian Prescriber. Subscribe now for free.